Verified Events

XCath’s Iris surgical robot enters FDA TAP programme

• Enrollment follows Iris’s September 2, 2026 Breakthrough Device designation.
• A dedicated FDA advisor and review-team engagement will cover development decisions, with facilitated input from payers, providers and other stakeholders.
• Iris remains under development and is not cleared for commercial distribution in any country.